Europe - OHE

We found for

The Socio-Economic Value of Adult Immunisation Programmes banner

News
April 2024

Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report

Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?

Insight
April 2024

Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

Insight
January 2024

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

Breaking the European Deadlock: Part 2 - Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?

Insight
January 2024

Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?

Slovak Republic

Insight
September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Blog 4

Insight
October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Insight
March 2021

Does Government Funding Increase Public Sector Development of New Medicines?

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

Read more

Health Policy and Regulation

Opportunities to Increase Efficiency in Healthcare

Read more

Insight
September 2018

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Read more

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Read more

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Read more

Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure

Read more

Improving Efficiency and Resource Allocation in Future Cancer Care

Read more